DOI · e01.org

Non-Clinical Contribution to Clinical Trials during Lead Optimization Phase

Lázara Martínez Muñoz · Behavioral Sciences · 2018

  • DOI 10.3390/bs8010017
  • Publisher Multidisciplinary Digital Publishing Institute
  • Type article
  • Issued 2018

Not cached yet. This record was fetched live for this request and is stored after the lookup. Reopening the page should serve the cached copy.

Behavioral Sciences · Multidisciplinary Digital Publishing Institute · article · 2018

Abstract

This manuscript comments on guidelines related to requirements for clinical trials for new drugs and the importance of considering regulatory criteria in the planning phase, in order to enhance the utility of data generated in basic research. Suggestions are made for optimizing regulatory management to improve the likelihood of acceptance of pre-clinical data prior to Clinical Phase I trials (early clinical trials).

Open the resolved locator · 10.3390/bs8010017

Metadata licence: OpenAlex metadata (CC0)

Registry
OpenAlex DOI index + API
Fetched
2026-11-19 20:17 UTC
Cache state
not cached yet (bulk-index+openalex)
Locator
https://doi.org/10.3390/bs8010017
Metadata licence
OpenAlex metadata (CC0)
Scope
Metadata as returned by the resolver; abstracts are never generated here.